News

Collaboration centers around providing assistance to multiple links in the clinical trial chain, from participants to providers

Development of additional 29,000 square feet addresses med tech company’s internal production capabilities

Recent FDA actions may finally usher in access boost to follow-on biologics in the US

R&D partnership with VaxEquity outlines plan to use saRNA as a go-to therapeutic

Polish facility will be based on GDP and ISO practices

Financial commitment expected to expand the development and commercialization pipeline for new medicines

UK location offers close proximity to London Heathrow Airport

Side effects were consistent with 16-25 age group

Both Comirnaty, Spikevax jabs had previously been authorized for use under Interim Order

Availability of space for new labs is a key selling point

Acquisition expected to help provide customers with a quicker clinical trial recruitment process

Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot

Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions

Latest construction plan continues CDMO’s vision for biopharma expansion

FDA’s recommended guidance is for a system that ‘does not exist, cannot be built by 2023, and poses unacceptable security and compliance risks,’ says alliance

Biotech firm to file regulatory dossier with officials around the world

CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand

Collaboration earns Adaptimmune an initial payday of $150 million

After previously going bankrupt, center is now under US ownership for the first time

Supply deal with Takeda to begin distribution in early 2022, pending shot approval

Drug maker to supply European Union with 60 million doses by end of Q3

Objective is to provide efficiency for analytics company’s medical information department

Swiss organization will take patient-centric approach towards developing injectables

Company’s prospective malaria and tuberculosis doses will be developed in Rwanda, Senegal

Irvine, CA, location will house 40,000 square feet of oral solid dosage forms

Agreement will focus on developing, manufacturing and commercializing biosimilars in the respiratory space

Meeting future expectations in pharmaceutical sustainability a key component of shipping collaboration

Project will center on equipment and technology improvements, says UK R&D and manufacturing accelerator